The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Pfkfb4 (PFKFB4) Functional Annotation in Rat (UniProt P25114)

1. Target verification and gene/protein identity

The research target is Pfkfb4, encoding 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4), a member of the mammalian PFKFB1–4 family of bifunctional enzymes that regulate levels of fructose-2,6-bisphosphate (F-2,6-BP). Multiple authoritative sources consistently describe PFKFB4 as the “testis” isoform (i.e., predominantly expressed in testes / initially detected in testes), aligning with the UniProt P25114 description provided by the user. (campos2023hittingthesweet pages 3-4, chesney2015targetingthesugar pages 1-2, crochet2015insightsintothe pages 11-18)

Important limitation (species specificity): within the retrieved full texts, most mechanistic and translational studies are in human and mouse cancer models; direct experimental studies explicitly referencing Rattus norvegicus UniProt P25114 were not retrieved in this run. Therefore, rat-specific assertions below are restricted to (i) well-supported family-level enzymology that is conserved across mammalian PFKFB isoforms and (ii) the strongly supported “testis isoform” identity for PFKFB4. (campos2023hittingthesweet pages 3-4, michels2006evolutionaryanalysisof pages 1-2)

2. Key concepts and definitions (current understanding)

2.1 What PFKFB4 is (bifunctional PFK-2/FBPase-2)

PFKFB enzymes are bifunctional homodimers with two independent catalytic domains: an N-terminal kinase (PFK-2) domain that synthesizes F-2,6-BP and a C-terminal phosphatase (FBPase-2) domain that degrades F-2,6-BP. (campos2023hittingthesweet pages 3-4, crochet2015insightsintothe pages 11-18)

2.2 Enzymatic reactions and EC numbers (primary biochemical function)

Fructose-2,6-bisphosphate is produced from fructose-6-phosphate by 6-phosphofructo-2-kinase (PFK-2; EC 2.7.1.105) and hydrolyzed by fructose-2,6-bisphosphatase (FBPase-2; EC 3.1.3.46); in mammals these opposing activities occur within the same bifunctional PFKFB enzymes. (michels2006evolutionaryanalysisof pages 1-2)

Accordingly, the appropriate reaction annotation for rat PFKFB4 is:
- Kinase activity (PFK-2): fructose-6-phosphate + ATP → fructose-2,6-bisphosphate + ADP (ATP-dependent phosphorylation of F6P to generate F-2,6-BP). (crochet2015insightsintothe pages 11-18, michels2006evolutionaryanalysisof pages 1-2)
- Phosphatase activity (FBPase-2): fructose-2,6-bisphosphate + H2O → fructose-6-phosphate + Pi (hydrolysis of F-2,6-BP back to F6P). (michels2006evolutionaryanalysisof pages 1-2)

2.3 What F-2,6-BP does (metabolic control point)

F-2,6-BP is a potent allosteric regulator of carbohydrate metabolism. At submicromolar concentrations, it stimulates glycolysis and inhibits gluconeogenesis by:
- acting as an allosteric activator of ATP-dependent phosphofructokinase-1 (PFK1), and
- inhibiting fructose-1,6-bisphosphatase. (michels2006evolutionaryanalysisof pages 1-2)

In cancer-metabolism-focused reviews, F-2,6-BP is described as the most potent activator of PFK1, and elevated F-2,6-BP can override ATP-mediated inhibition of PFK1, thereby increasing glycolytic flux. (campos2023hittingthesweet pages 3-4, chesney2015targetingthesugar pages 1-2)

3. Functional annotation: biological processes, localization, and pathways

3.1 Cellular localization (where the gene product acts)

Across eukaryotes including mammals, PFK-2/FBPase-2 activities are described as cytosolic. This supports a core annotation that rat PFKFB4 acts primarily in the cytosolic compartment to control F-2,6-BP levels and thereby regulate glycolysis/gluconeogenesis flux. (michels2006evolutionaryanalysisof pages 1-2)

However, tumor tissue immunohistochemistry data in colon adenocarcinoma reported PFKFB4 staining in both cytoplasm and nucleus, with stronger nuclear staining in that context; this should be interpreted as context- and species-specific (human cancer tissue) and not automatically generalized to normal rat testis. (gu2023differentialrolesof pages 2-4)

3.2 Tissue expression (testis-type isozyme)

PFKFB4 is repeatedly described as being mainly expressed in the testes and as the testis isoform within the four PFKFB genes, supporting the “testis-type” annotation for rat Pfkfb4 (P25114). (campos2023hittingthesweet pages 3-4, crochet2015insightsintothe pages 11-18, chesney2015targetingthesugar pages 1-2)

3.3 Pathways and mechanistic role

At the pathway level, PFKFB4 regulates glycolytic flux by controlling the concentration of F-2,6-BP, which directly tunes PFK1 activity. (campos2023hittingthesweet pages 3-4, crochet2015insightsintothe pages 11-18)

Beyond glycolysis control, expert synthesis in the literature frames PFKFB4 as contributing to metabolic “fine-tuning” by supporting diversion of glucose carbon toward the pentose phosphate pathway (PPP) to generate NADPH and help buffer oxidative stress (ROS), particularly in cancer contexts. (yi20196phosphofructo2kinasefructose26biphosphatase3and pages 1-2, campos2023hittingthesweet pages 4-6)

4. Recent developments and latest research (prioritizing 2023–2024)

4.1 2023 review: spatial/temporal control of glycolysis highlights PFKFB4

A 2023 peer-reviewed review on PFK1 regulation emphasizes PFKFB enzymes as key controllers of F-2,6-BP, notes isoform specialization (including PFKFB4 being mainly testicular), and highlights PFKFB3/4 as frequently overexpressed and functionally important in cancers. (Publication: 2023-12; URL: https://doi.org/10.3390/cancers16010016) (campos2023hittingthesweet pages 3-4, campos2023hittingthesweet pages 4-6)

4.2 2023 primary study: PFKFB4 as a biomarker in colon adenocarcinoma

A 2023 Scientific Reports study measured PFKFB4 by immunohistochemistry (IHC) in 79 colon adenocarcinoma (COAD) tumors and 15 adjacent normal tissues (15 matched pairs). PFKFB4 staining was detected in cytoplasm and nucleus and reported as higher in tumor tissues. (Publication: 2023-09; URL: https://doi.org/10.1038/s41598-023-43619-4) (gu2023differentialrolesof pages 2-4, gu2023differentialrolesof pages 8-9)

The same study used Kaplan–Meier plotter datasets with cohort sizes of RFS n=1302, OS n=550, and PPS n=145 for PFKFB4 (Affymetrix ID 206246_at), and it discusses complex/stage-dependent prognostic relationships as well as correlations with immune infiltration. (gu2023differentialrolesof pages 8-9)

5. Current applications and real-world implementations

5.1 PFKFB4 as a therapeutic target: small-molecule inhibition (preclinical)

A concrete translational implementation is development of small-molecule inhibitors targeting PFKFB4. A 2015 study reported 5MPN (5-(n-(8-methoxy-4-quinolyl)amino)pentyl nitrate) as a first-in-class, selective PFKFB4 inhibitor identified by structure-based virtual screening. (Publication: 2015-06; URL: https://doi.org/10.18632/oncotarget.4534) (chesney2015targetingthesugar pages 1-2)

Key reported implementation details include:
- Enzymatic potency: Ki = 8.6 ± 1.9 µM against PFKFB4. (chesney2015targetingthesugar pages 1-2)
- Selectivity: at 10 µM, 5MPN did not inhibit PFK1 or PFKFB3 in the assays described, and it did not inhibit a panel of 97 protein kinases at 10 µM. (chesney2015targetingthesugar pages 1-2)
- Cellular pharmacodynamics: in H460 lung adenocarcinoma cells, 5MPN caused dose-dependent reductions in intracellular F-2,6-BP at 24 h (see quantitative values below). (chesney2015targetingthesugar pages 1-2)
- In vivo implementation: oral (gavage) dosing in mouse tumor models was used (e.g., 120 mg/kg PO in a reported setting) with metabolic imaging (FDG-PET) and tumor growth endpoints; the study reports suppressed tumor glucose uptake/metabolism and tumor growth without gross toxicity in the excerpted text. (chesney2015targetingthesugar pages 6-6, chesney2015targetingthesugar pages 6-8)

5.2 PFKFB4 as a biomarker / expression marker

The 2023 COAD study provides an example of PFKFB4 use as an IHC-measured marker in real clinical tissue cohorts and integrates public survival datasets and immune-infiltration analyses, illustrating current “real-world” usage patterns of PFKFB4 in cancer bioinformatics/biomarker workflows. (gu2023differentialrolesof pages 2-4, gu2023differentialrolesof pages 8-9)

6. Expert opinions and analysis (authoritative synthesis)

6.1 PFKFB4 as a “valve” balancing glycolysis and PPP

A well-cited review frames PFKFB3 and PFKFB4 as a pair of “valves” for tuning glucose metabolism in cancer: PFKFB3 is generally characterized as having a high kinase bias promoting glycolysis, whereas PFKFB4 is associated with shifting glucose utilization toward PPP/NADPH production and redox balance. This conceptual model is used by experts to explain why some tumors require PFKFB4 even when it is not the strongest glycolysis driver. (Publication: 2019-02; URL: https://doi.org/10.1016/j.molmet.2018.11.013) (yi20196phosphofructo2kinasefructose26biphosphatase3and pages 1-2)

6.2 Functional requirement in cancer models: redox and survival

A primary functional screen in metastatic prostate cancer cell lines identified PFKFB4 as selectively required for cancer cell survival and proposed a role in balancing glycolysis with antioxidant production to maintain redox homeostasis; depletion inhibited tumor growth in xenograft models, supporting the idea that PFKFB4 can be a metabolic dependency in vivo. (Publication: 2012-04; URL: https://doi.org/10.1158/2159-8290.CD-11-0234) (ros2012functionalmetabolicscreen pages 1-3)

6.3 Regulation themes: hypoxia and p53 loss (cancer context)

A review of metabolic vulnerabilities in breast cancer reports that PFKFB4 (i) is induced by hypoxia and (ii) is induced by loss of p53, and notes enrichment in hypoxic tumor regions; it further summarizes functional studies where PFKFB4 depletion reduces lactate production and metastatic burden in tumor models. (Publication: 2026-02; URL: https://doi.org/10.3390/curroncol33020129) (guo2026metabolicvulnerabilitiesas pages 4-6)

7. Quantitative statistics and data points from recent and influential studies

7.1 Inhibitor pharmacology (PFKFB4 inhibitor 5MPN)

In H460 lung adenocarcinoma cells, intracellular F-2,6-BP at 24 h decreased dose-dependently with 5MPN:
- DMSO: 6.1 ± 0.2 pmol/mg protein
- 5 µM: 2.3 ± 0.05 pmol/mg
- 10 µM: 1.52 ± 0.2 pmol/mg
- 20 µM: 0.75 ± 0.09 pmol/mg
- 30 µM: 0.43 ± 0.1 pmol/mg
(Publication: 2015-06; URL: https://doi.org/10.18632/oncotarget.4534) (chesney2015targetingthesugar pages 1-2)

The same work reports Ki = 8.6 ± 1.9 µM for 5MPN inhibition of PFKFB4. (chesney2015targetingthesugar pages 1-2)

7.2 Colon adenocarcinoma tissue cohort and survival dataset sizes (2023)

The 2023 COAD IHC study includes:
- Tissue cohort: 79 tumors, 15 adjacent normal tissues, including 15 matched tumor/normal pairs. (gu2023differentialrolesof pages 2-4)
- Survival dataset cohort sizes (Kaplan–Meier plotter): RFS n=1302, OS n=550, PPS n=145 for PFKFB4 (Affymetrix 206246_at). (gu2023differentialrolesof pages 8-9)

8. Evidence summary table (for annotation workflows)

The following evidence-backed table consolidates the functional annotation elements (reaction, metabolite role, localization, regulation, pathways, and applications) and highlights 2023–2024 sources.

Table: This table summarizes evidence-backed functional annotation for rat Pfkfb4/PFKFB4 (UniProt P25114), integrating core enzymology with recent 2023-2024 literature, translational relevance, and quantitative findings. It is useful for separating well-supported family-level functions from more limited direct rat-specific evidence.

9. Practical functional-annotation conclusions for rat Pfkfb4 (UniProt P25114)

1. Molecular function (core): annotate rat PFKFB4 as a bifunctional PFK-2/FBPase-2 enzyme that controls F-2,6-BP levels via EC 2.7.1.105 and 3.1.3.46 activities; substrates/products center on fructose-6-phosphate ↔ fructose-2,6-bisphosphate with ATP usage in the kinase direction. (michels2006evolutionaryanalysisof pages 1-2, crochet2015insightsintothe pages 11-18)
2. Biological process: regulation of glycolysis and gluconeogenesis through F-2,6-BP-mediated allosteric control of PFK1 and inhibition of fructose-1,6-bisphosphatase. (michels2006evolutionaryanalysisof pages 1-2, campos2023hittingthesweet pages 3-4)
3. Cellular component: primary evidence supports a cytosolic enzyme family location; nuclear staining has been observed in a human COAD context but should not be treated as canonical for rat without direct validation. (michels2006evolutionaryanalysisof pages 1-2, gu2023differentialrolesof pages 2-4)
4. Tissue specificity: PFKFB4 is consistently characterized as testis-enriched / testis isoform, matching the UniProt target context for rat Pfkfb4. (campos2023hittingthesweet pages 3-4, chesney2015targetingthesugar pages 1-2)
5. Applied relevance: although most work is outside rat physiology, PFKFB4 is a prominent target in cancer metabolism research, including preclinical inhibitor development (5MPN) and biomarker studies (e.g., COAD IHC and survival datasets). (chesney2015targetingthesugar pages 1-2, gu2023differentialrolesof pages 8-9)

References (URLs and dates in-line)

Key recent sources emphasized above include Campos & Albrecht (2023-12, https://doi.org/10.3390/cancers16010016) and Gu et al. (2023-09, https://doi.org/10.1038/s41598-023-43619-4), with mechanistic/translational anchors including Michels & Rigden (2006-03, https://doi.org/10.1080/15216540600688280), Ros et al. (2012-04, https://doi.org/10.1158/2159-8290.CD-11-0234), Yi et al. (2019-02, https://doi.org/10.1016/j.molmet.2018.11.013), and Chesney et al. (2015-06, https://doi.org/10.18632/oncotarget.4534). (michels2006evolutionaryanalysisof pages 1-2, ros2012functionalmetabolicscreen pages 1-3, yi20196phosphofructo2kinasefructose26biphosphatase3and pages 1-2, chesney2015targetingthesugar pages 1-2, campos2023hittingthesweet pages 3-4, gu2023differentialrolesof pages 8-9)

References

1. (campos2023hittingthesweet pages 3-4): Melissa Campos and Lauren V. Albrecht. Hitting the sweet spot: how glucose metabolism is orchestrated in space and time by phosphofructokinase-1. Cancers, 16:16, Dec 2023. URL: https://doi.org/10.3390/cancers16010016, doi:10.3390/cancers16010016. This article has 29 citations.

2. (chesney2015targetingthesugar pages 1-2): Jason Chesney, Jennifer Clark, Lilibeth Lanceta, John O. Trent, and Sucheta Telang. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (pfkfb4) inhibitor. Oncotarget, 6:18001-18011, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4534, doi:10.18632/oncotarget.4534. This article has 55 citations.

3. (crochet2015insightsintothe pages 11-18): Robert Crochet. Insights into the development of chemotherapeutics targeting pfkfb enzymes. ArXiv, 2015. URL: https://doi.org/10.31390/gradschool_dissertations.311, doi:10.31390/gradschool_dissertations.311. This article has 1 citations.

4. (michels2006evolutionaryanalysisof pages 1-2): Paul A. M. Michels and Daniel J. Rigden. Evolutionary analysis of fructose 2,6‐bisphosphate metabolism. IUBMB Life, 58:133-141, Mar 2006. URL: https://doi.org/10.1080/15216540600688280, doi:10.1080/15216540600688280. This article has 28 citations and is from a peer-reviewed journal.

5. (gu2023differentialrolesof pages 2-4): Xiaojing Gu, Xingchen Dai, Yongli Huang, Yuhuan Zhang, Lintao Dong, Chanchan Gao, and Fang Wang. Differential roles of highly expressed pfkfb4 in colon adenocarcinoma patients. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-43619-4, doi:10.1038/s41598-023-43619-4. This article has 10 citations and is from a peer-reviewed journal.

6. (yi20196phosphofructo2kinasefructose26biphosphatase3and pages 1-2): Mei Yi, Yuanyuan Ban, Yixin Tan, W. Xiong, Gui-yuan Li, and B. Xiang. 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: a pair of valves for fine-tuning of glucose metabolism in human cancer. Molecular Metabolism, 20:1-13, Feb 2019. URL: https://doi.org/10.1016/j.molmet.2018.11.013, doi:10.1016/j.molmet.2018.11.013. This article has 196 citations and is from a domain leading peer-reviewed journal.

7. (campos2023hittingthesweet pages 4-6): Melissa Campos and Lauren V. Albrecht. Hitting the sweet spot: how glucose metabolism is orchestrated in space and time by phosphofructokinase-1. Cancers, 16:16, Dec 2023. URL: https://doi.org/10.3390/cancers16010016, doi:10.3390/cancers16010016. This article has 29 citations.

8. (gu2023differentialrolesof pages 8-9): Xiaojing Gu, Xingchen Dai, Yongli Huang, Yuhuan Zhang, Lintao Dong, Chanchan Gao, and Fang Wang. Differential roles of highly expressed pfkfb4 in colon adenocarcinoma patients. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-43619-4, doi:10.1038/s41598-023-43619-4. This article has 10 citations and is from a peer-reviewed journal.

9. (chesney2015targetingthesugar pages 6-6): Jason Chesney, Jennifer Clark, Lilibeth Lanceta, John O. Trent, and Sucheta Telang. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (pfkfb4) inhibitor. Oncotarget, 6:18001-18011, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4534, doi:10.18632/oncotarget.4534. This article has 55 citations.

10. (chesney2015targetingthesugar pages 6-8): Jason Chesney, Jennifer Clark, Lilibeth Lanceta, John O. Trent, and Sucheta Telang. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (pfkfb4) inhibitor. Oncotarget, 6:18001-18011, Jun 2015. URL: https://doi.org/10.18632/oncotarget.4534, doi:10.18632/oncotarget.4534. This article has 55 citations.

11. (ros2012functionalmetabolicscreen pages 1-3): Susana Ros, Claudio R. Santos, Sofia Moco, Franziska Baenke, Gavin Kelly, Michael Howell, Nicola Zamboni, and Almut Schulze. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discovery, 2(4):328-343, Apr 2012. URL: https://doi.org/10.1158/2159-8290.cd-11-0234, doi:10.1158/2159-8290.cd-11-0234. This article has 243 citations and is from a highest quality peer-reviewed journal.

12. (guo2026metabolicvulnerabilitiesas pages 4-6): Sabrina Guo and Christina L. Addison. Metabolic vulnerabilities as a therapeutic target in breast cancer. Current Oncology, 33:129, Feb 2026. URL: https://doi.org/10.3390/curroncol33020129, doi:10.3390/curroncol33020129. This article has 2 citations.

13. (gu2023differentialrolesof pages 1-2): Xiaojing Gu, Xingchen Dai, Yongli Huang, Yuhuan Zhang, Lintao Dong, Chanchan Gao, and Fang Wang. Differential roles of highly expressed pfkfb4 in colon adenocarcinoma patients. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-43619-4, doi:10.1038/s41598-023-43619-4. This article has 10 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. michels2006evolutionaryanalysisof pages 1-2
2. gu2023differentialrolesof pages 2-4
3. gu2023differentialrolesof pages 8-9
4. chesney2015targetingthesugar pages 1-2
5. ros2012functionalmetabolicscreen pages 1-3
6. guo2026metabolicvulnerabilitiesas pages 4-6
7. campos2023hittingthesweet pages 3-4
8. crochet2015insightsintothe pages 11-18
9. campos2023hittingthesweet pages 4-6
10. chesney2015targetingthesugar pages 6-6
11. chesney2015targetingthesugar pages 6-8
12. gu2023differentialrolesof pages 1-2
13. https://doi.org/10.3390/cancers16010016
14. https://doi.org/10.1038/s41598-023-43619-4
15. https://doi.org/10.18632/oncotarget.4534
16. https://doi.org/10.1016/j.molmet.2018.11.013
17. https://doi.org/10.1158/2159-8290.CD-11-0234
18. https://doi.org/10.3390/curroncol33020129
19. https://doi.org/10.1080/15216540600688280;
20. https://doi.org/10.3390/cancers16010016;
21. https://doi.org/10.31390/gradschool_dissertations.311
22. https://doi.org/10.18632/oncotarget.4534;
23. https://doi.org/10.1016/j.molmet.2018.11.013;
24. https://doi.org/10.1158/2159-8290.CD-11-0234;
25. https://doi.org/10.1038/s41598-023-43619-4;
26. https://doi.org/10.1080/15216540600688280
27. https://doi.org/10.3390/cancers16010016,
28. https://doi.org/10.18632/oncotarget.4534,
29. https://doi.org/10.31390/gradschool_dissertations.311,
30. https://doi.org/10.1080/15216540600688280,
31. https://doi.org/10.1038/s41598-023-43619-4,
32. https://doi.org/10.1016/j.molmet.2018.11.013,
33. https://doi.org/10.1158/2159-8290.cd-11-0234,
34. https://doi.org/10.3390/curroncol33020129,